Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18774608 | COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES | July 2024 | January 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18774646 | COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES | July 2024 | April 2025 | Allow | 9 | 2 | 0 | Yes | No |
| 18774629 | COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES | July 2024 | March 2025 | Allow | 8 | 2 | 0 | Yes | No |
| 18444471 | COMPOSITIONS COMPRISING PHARMACEUTICALLY ACCEPTABLE SALTS OF AMYLIN ANALOGS AND USES THEREOF | February 2024 | November 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18439344 | Nano-sized Chitosan/VS2 nanocomposite like flowers for Antimicrobial Applications | February 2024 | November 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18439336 | Method for Making Nano-sized Chitosan/VS2 Nanocomposites | February 2024 | October 2024 | Allow | 8 | 2 | 0 | No | No |
| 18507324 | Nano-sized Chitosan/VS2 nanocomposite like flowers for Potential Pharmaceutical Applications | November 2023 | July 2024 | Allow | 9 | 2 | 1 | Yes | No |
| 18341437 | COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES | June 2023 | May 2024 | Allow | 10 | 1 | 1 | Yes | No |
| 18324097 | Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof | May 2023 | March 2024 | Allow | 10 | 2 | 1 | No | No |
| 18305919 | Production of Biosimilar Ustekinumab in CHO Cells | April 2023 | June 2024 | Allow | 13 | 2 | 0 | Yes | No |
| 18300064 | PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USE | April 2023 | January 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18161036 | PROTEIN-TYPE NANOPARTICLES, PREPARATION METHODS, AND APPLICATION THEREOF | January 2023 | December 2023 | Allow | 11 | 2 | 1 | No | No |
| 18086031 | HIGH CONCENTRATION ANTI-C5 ANTIBODY FORMULATIONS | December 2022 | February 2024 | Allow | 14 | 1 | 1 | Yes | No |
| 18002248 | COMBINING IPSC DERIVED EFFECTOR CELL TYPES FOR IMMUNOTHERAPY USE | December 2022 | December 2024 | Allow | 24 | 2 | 1 | Yes | Yes |
| 18054101 | COMPOSITIONS AND METHODS FOR ENHANCING TRIPLEX AND NUCLEASE-BASED GENE EDITING | November 2022 | November 2024 | Abandon | 24 | 2 | 1 | No | No |
| 17863587 | METHOD FOR PURIFYING IMMUNOGLOBULIN SOLUTIONS | July 2022 | June 2025 | Abandon | 35 | 0 | 1 | No | No |
| 17831645 | EXCIPIENT COMPOUNDS FOR PROTEIN PROCESSING | June 2022 | June 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17832463 | METHODS AND FORMULATIONS FOR REDUCING RECONSTITUTION TIME OF LYOPHILIZED POLYPEPTIDES | June 2022 | June 2025 | Allow | 36 | 2 | 0 | Yes | No |
| 17731671 | FORMULATION CONTAINING TLR AGONIST AND METHODS OF USE | April 2022 | May 2025 | Allow | 37 | 2 | 1 | Yes | No |
| 17732224 | Thermostable Vaccine Compositions and Methods of Preparing The Same | April 2022 | June 2025 | Allow | 38 | 1 | 1 | Yes | No |
| 17726741 | HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) | April 2022 | March 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17675488 | USE OF THE IL-1BETA BINDING ANTIBODY CANAKINUMAB FOR TREATING OR ALLEVIATING SYMPTOMS OF PULMONARY SARCOIDOSIS | February 2022 | February 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17584286 | PROTEIN FORMULATIONS AND METHODS OF MAKING SAME | January 2022 | February 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17572350 | Production of Biosimilar Ustekinumab In CHO Cells | January 2022 | March 2025 | Abandon | 38 | 1 | 1 | No | No |
| 17552392 | METHODS FOR PROVIDING POLYMERIC SYNTHETIC NANOCARRIERS FOR GENERATING ANTIGEN-SPECIFIC TOLERANCE IMMUNE RESPONSES | December 2021 | May 2025 | Abandon | 41 | 1 | 1 | No | No |
| 17542632 | VISCOSITY REDUCTION OF HIGHLY CONCENTRATED PROTEIN FORMULATIONS | December 2021 | December 2024 | Allow | 36 | 2 | 1 | No | No |
| 17457456 | USE OF AMINO ACIDS AS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS CONTAINING HIGH CONCENTRATIONS OF PROTEIN-BASED THERAPEUTIC AGENTS | December 2021 | May 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17534218 | NANOENCAPSULATION OF ANTIGEN-BINDING MOLECULES | November 2021 | August 2024 | Abandon | 33 | 0 | 1 | No | No |
| 17455713 | FORMULATIONS OF MONOCLONAL ANTIBODIES | November 2021 | February 2025 | Abandon | 39 | 3 | 0 | No | No |
| 17519141 | HIGH CONCENTRATION IMMUNOGLOBULIN COMPOSITION FOR PHARMACEUTICAL APPLICATION | November 2021 | October 2024 | Allow | 35 | 2 | 1 | No | No |
| 17514957 | PROCESS FOR PREPARING AN IMMUNOGLOBULIN PREPARATION | October 2021 | September 2024 | Allow | 34 | 2 | 0 | No | No |
| 17503759 | Novel Formulations Which Stabilize Low Dose Antibody Compositions | October 2021 | April 2025 | Abandon | 41 | 2 | 1 | No | No |
| 17470270 | METHODS AND COMPOSITIONS FOR TARGETING T-CELL CANCERS | September 2021 | June 2024 | Abandon | 33 | 0 | 1 | No | No |
| 17437634 | PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-LINGO-1 ANTIBODIES | September 2021 | May 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17460979 | IMMUNOGENIC COMPOSITION FOR THE TREATMENT OF CANCER AND METHODS OF PREPARING THE SAME | August 2021 | March 2024 | Allow | 30 | 1 | 0 | No | No |
| 17393888 | METHODS FOR PREPARING ALUMINUM PRECIPITATE COMPOUNDS FOR USE IN THERAPEUTICS AND VACCINES | August 2021 | January 2025 | Allow | 42 | 3 | 1 | Yes | No |
| 17391663 | NANOPARTICLES, CONTROLLED-RELEASE DOSAGE FORMS, AND METHODS FOR DELIVERING AN IMMUNOTHERAPEUTIC AGENT | August 2021 | January 2025 | Abandon | 42 | 2 | 1 | No | No |
| 17386385 | COMPOSITIONS AND METHODS FOR STABILIZING PROTEIN-CONTAINING FORMULATIONS | July 2021 | November 2023 | Allow | 28 | 2 | 0 | No | No |
| 17378025 | STABLE LIQUID ANTIBODY FORMULATION | July 2021 | February 2024 | Abandon | 31 | 1 | 0 | No | No |
| 17350781 | LIPOSOME COMPOSITIONS COMPRISING PAM2CYS OR PAM3CYS ADJUVANT AND METHODS FOR INDUCING A HUMORAL IMMUNE RESPONSE | June 2021 | August 2024 | Abandon | 38 | 2 | 0 | No | No |
| 17332521 | EXCIPIENT COMPOUNDS FOR PROTEIN PROCESSING | May 2021 | November 2024 | Abandon | 42 | 2 | 1 | No | No |
| 17320693 | STABILIZED ANTIBODY COMPOSITIONS | May 2021 | January 2024 | Allow | 32 | 2 | 0 | No | No |
| 17316585 | Thermostable Vaccine Compositions and Methods of Preparing same | May 2021 | May 2024 | Allow | 36 | 1 | 1 | Yes | No |
| 17291194 | ANTI-PTK7 IMMUNE CELL CANCER THERAPY | May 2021 | March 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17246288 | METHODS AND COMPOSITIONS FOR INCREASING IDURONATE 2-SULFATASE ACTIVITY IN THE CNS | April 2021 | March 2024 | Allow | 34 | 2 | 0 | Yes | No |
| 17233008 | Composition Comprising an Antibody | April 2021 | July 2024 | Allow | 39 | 2 | 0 | Yes | No |
| 17225887 | Stabilized Formulations Containing Anti-Interleukin-6 Receptor (IL-6R) Antibodies | April 2021 | April 2024 | Allow | 36 | 2 | 0 | No | No |
| 17224900 | FORMULATIONS OF MONOCLONAL ANTIBODIES | April 2021 | October 2024 | Abandon | 43 | 2 | 1 | No | No |
| 17211399 | AQUEOUS PHARMACEUTICAL FORMULATIONS | March 2021 | December 2023 | Abandon | 33 | 0 | 1 | No | No |
| 17211459 | METHODS OF ADMINISTERING IMMUNOSUPPRESSANTS HAVING A SPECIFIED PHARMACODYNAMIC EFFECTIVE LIFE AND THERAPEUTIC MACROMOLECULES FOR THE INDUCTION OF IMMUNE TOLERANCE | March 2021 | January 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17200552 | CONJUGATE VACCINE TARGETING A DISEASE-CAUSING BIOLOGICAL PROTEIN | March 2021 | March 2024 | Allow | 36 | 1 | 1 | Yes | No |
| 17197603 | COMPOSITIONS OF IL-6/IL-6R ANTIBODIES AND METHODS OF USE THEREOF | March 2021 | November 2024 | Abandon | 44 | 2 | 1 | No | No |
| 17191589 | IMMUNOGLOBULIN FORMULATION AND METHOD OF PREPARATION THEREOF | March 2021 | September 2024 | Abandon | 43 | 2 | 1 | No | No |
| 17179223 | NOVEL BISPECIFIC ANTIGEN BINDING MOLECULES CAPABLE OF SPECIFIC BINDING TO CD40 AND TO FAP | February 2021 | July 2024 | Allow | 41 | 2 | 1 | Yes | No |
| 17177022 | HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY LIQUID FORMULATIONS | February 2021 | November 2023 | Abandon | 33 | 0 | 1 | No | No |
| 17175162 | EXCIPIENT COMPOUNDS FOR BIOPOLYMER FORMULATIONS | February 2021 | August 2023 | Allow | 30 | 6 | 1 | Yes | No |
| 17170667 | COMPOSITIONS AND METHODS FOR TREATING POMPE DISEASE | February 2021 | November 2024 | Allow | 45 | 3 | 1 | Yes | No |
| 17165704 | PROTEIN-NANOPARTICLE CONJUGATE PURIFICATION METHODS | February 2021 | October 2023 | Allow | 32 | 2 | 0 | No | No |
| 17155432 | STABLE ANTIBODY FORMULATION | January 2021 | February 2025 | Allow | 49 | 5 | 0 | Yes | No |
| 17152054 | COMPOSITIONS COMPRISING AN ANTI-C5 ANTIBODY | January 2021 | October 2023 | Abandon | 33 | 2 | 0 | No | No |
| 17260334 | FCRN ANTIBODY COMPOSITIONS | January 2021 | April 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17128736 | METHOD FOR TREATMENT OF A LEUKOCYTE RELATED DISEASE BY DELIVERY OF NUCLEIC ACID MOLECULES TO LEUKOCYTES USING TARGETED LIPID PARTICLES | December 2020 | April 2024 | Allow | 40 | 2 | 1 | Yes | No |
| 17254508 | METHODS OF PRODUCING ANTI-C5 ANTIBODIES | December 2020 | April 2025 | Allow | 51 | 2 | 0 | No | No |
| 17116587 | AQUEOUS PHARMACEUTICAL FORMULATION COMPRISING ANTI-PD-L1 ANTIBODY AVELUMAB | December 2020 | November 2023 | Abandon | 35 | 1 | 0 | No | No |
| 17106105 | Engineered Biofilms | November 2020 | March 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17105358 | COMPOSITIONS AND METHODS FOR PRODUCING A COMPOSITION | November 2020 | February 2024 | Allow | 39 | 2 | 1 | Yes | No |
| 17101966 | ANTI-PDL1 ANTIBODY FORMULATIONS | November 2020 | October 2023 | Abandon | 35 | 0 | 1 | No | No |
| 17101063 | Liquid Protein Formulations Containing Viscosity-Lowering Agents | November 2020 | June 2024 | Abandon | 43 | 2 | 1 | No | No |
| 17091553 | ANTI-ABETA THERAPEUTIC VACCINES | November 2020 | March 2024 | Allow | 40 | 2 | 1 | Yes | No |
| 17052696 | STABLE HYBRID FC FUSION G-CSF FORMULATION | November 2020 | December 2024 | Allow | 50 | 3 | 0 | No | No |
| 17073618 | Liquid Protein Formulations Containing 4-Ethyl-4-Methylmorpholinium Methylcarbonate (EMMC) | October 2020 | October 2023 | Allow | 36 | 2 | 1 | No | No |
| 17047462 | QUALITATIVE ANALYSIS OF PROTEINS | October 2020 | June 2025 | Allow | 56 | 2 | 1 | Yes | Yes |
| 17067058 | Liquid Protein Formulations Containing Cyclic Adenosine Monophosphate (cAMP) or Adenosine Triphosphate (ATP) | October 2020 | July 2023 | Allow | 33 | 1 | 1 | No | No |
| 17040702 | FULL FLOW-THROUGH PROCESS FOR PURIFYING RECOMBINANT PROTEINS | September 2020 | April 2025 | Allow | 55 | 4 | 1 | Yes | No |
| 17017465 | PROCESS FOR CONCENTRATION OF ANTIBODIES AND THERAPEUTIC PRODUCTS THEREOF | September 2020 | February 2024 | Allow | 41 | 2 | 1 | Yes | No |
| 17011014 | EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS | September 2020 | August 2024 | Abandon | 48 | 1 | 1 | No | No |
| 16977142 | METHODS FOR PURIFYING RECOMBINANT POLYPEPTIDES | September 2020 | April 2024 | Abandon | 43 | 1 | 0 | No | No |
| 16943378 | HIGHLY CONCENTRATED PHARMACEUTICAL FORMULATIONS | July 2020 | December 2023 | Abandon | 40 | 1 | 1 | No | No |
| 16954868 | LIQUID FORMULATIONS OF ANTI-CD200 ANTIBODIES | June 2020 | July 2024 | Allow | 49 | 4 | 1 | Yes | No |
| 16772407 | METHODS OF INDUCING IMMUNE TOLERANCE AND REDUCING ANTI-DRUG ANTIBODY RESPONSE | June 2020 | February 2025 | Abandon | 56 | 4 | 1 | No | No |
| 16891249 | MULTISPECIFIC PROTEINS | June 2020 | October 2023 | Abandon | 40 | 1 | 1 | No | No |
| 16767994 | LYOPHILIZED FORMULATION OF A MONOCLONAL ANTIBODY AGAINST TRANSTHYRETIN | May 2020 | August 2023 | Allow | 39 | 2 | 1 | Yes | No |
| 16765786 | PHARMACEUTICAL COMPOSITIONS | May 2020 | August 2023 | Allow | 39 | 2 | 1 | Yes | No |
| 16876839 | ANTI-CD3 ANTIBODY FORMULATIONS | May 2020 | March 2025 | Abandon | 58 | 4 | 1 | Yes | No |
| 16876812 | Methods for Targeted Delivery of Agents to Degraded Elastic Fibers | May 2020 | January 2024 | Allow | 44 | 2 | 1 | Yes | No |
| 15931062 | METHODS FOR PURIFYING ANTIBODIES | May 2020 | January 2025 | Allow | 56 | 3 | 0 | Yes | No |
| 16763193 | AFLIBERCEPT FORMULATIONS CONTAINING A LYSINE SALT AS TONICIFYING AGENT AND USES THEREOF | May 2020 | August 2024 | Allow | 52 | 3 | 1 | Yes | No |
| 16859750 | DOSAGE REGIMENS FOR AND COMPOSITIONS INCLUDING ANTI-RSV ANTIBODIES | April 2020 | February 2024 | Allow | 46 | 3 | 1 | Yes | No |
| 16858349 | TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE OR PREVENT ANAPHYLAXIS IN RESPONSE TO A NON-ALLERGENIC ANTIGEN | April 2020 | December 2023 | Abandon | 43 | 5 | 1 | No | Yes |
| 16852196 | Peptide Conjugated Particles | April 2020 | July 2023 | Allow | 39 | 2 | 1 | Yes | No |
| 16756409 | Pharmaceutical Composition of Humanized Monoclonal Anti-PD-L1 Antibody | April 2020 | August 2024 | Allow | 52 | 2 | 2 | Yes | No |
| 16839249 | Method of Administration of an Anti-IFN-alpha/-omega Antibody | April 2020 | September 2024 | Allow | 53 | 4 | 1 | Yes | No |
| 16815635 | NOVEL METHODS FOR INDUCING AN IMMUNE RESPONSE | March 2020 | July 2023 | Allow | 40 | 2 | 1 | No | No |
| 16640422 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE REGIMENS CONTAINING ANTI-ALPHA(V)BETA(6) ANTIBODIES | February 2020 | October 2023 | Abandon | 44 | 2 | 1 | No | No |
| 16638339 | BRAF-SPECIFIC TCRS AND USES THEREOF | February 2020 | April 2025 | Allow | 60 | 2 | 1 | Yes | No |
| 16778128 | OPTIMIZED METHOD FOR ANTIBODY CAPTURING BY MIXED MODE CHROMATOGRAPHY | January 2020 | August 2024 | Allow | 54 | 2 | 0 | Yes | No |
| 16632851 | POLYMERIC NANOPARTICLES FOR ENHANCED CANCER IMMUNOTHERAPY | January 2020 | November 2023 | Allow | 45 | 4 | 1 | Yes | No |
| 16487990 | STABILIZED ANTIBODY SOLUTIONS | January 2020 | November 2023 | Abandon | 51 | 3 | 1 | No | No |
| 16715580 | PROTEIN SOLUTION FORMULATION CONTAINING HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY | December 2019 | December 2023 | Allow | 48 | 3 | 1 | Yes | No |
| 16697999 | STABILIZED AQUEOUS ANTIBODY COMPOSITIONS | November 2019 | September 2023 | Allow | 46 | 3 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KIM, YUNSOO.
With a 57.1% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 32.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner KIM, YUNSOO works in Art Unit 1641 and has examined 195 patent applications in our dataset. With an allowance rate of 75.9%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 42 months.
Examiner KIM, YUNSOO's allowance rate of 75.9% places them in the 34% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by KIM, YUNSOO receive 2.85 office actions before reaching final disposition. This places the examiner in the 93% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by KIM, YUNSOO is 42 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +43.3% benefit to allowance rate for applications examined by KIM, YUNSOO. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 22.5% of applications are subsequently allowed. This success rate is in the 20% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 61.7% of cases where such amendments are filed. This entry rate is in the 84% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 120.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 80% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 80.0% of appeals filed. This is in the 68% percentile among all examiners. Of these withdrawals, 57.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 52.0% are granted (fully or in part). This grant rate is in the 64% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 6.2% of allowed cases (in the 91% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.4% of allowed cases (in the 60% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.